Relmada Therapeutics Inc.
09/02/2025 | Press release | Distributed by Public on 09/02/2025 05:31
Regulation FD Disclosure (Form 8-K)
Item 7.01 Regulation FD Disclosure.
On August 29, 2025, Raj S. Pruthi, MD, Chief Medical Officer-Urology of Relmada Therapeutics, Inc. (the "Company"), purchased in open market transactions 55,000 shares of the Company's common stock, $0.001 par value per share.
In accordance with General Instruction B.2 of Form 8-K, the information in this Item 7.01 of this Current Report on Form 8-K is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Relmada Therapeutics Inc. published this content on September 02, 2025, and is solely responsible for the information contained herein. Distributed via SEC EDGAR on September 02, 2025 at 11:31 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]